Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk reports ‘significant improvement with NovoMix 30’

Novo Nordisk reports ‘significant improvement with NovoMix 30’

10th September 2008

Novo Nordisk has announced the publication of new data from the Improve trial at the annual meeting of the European Association for the Study of Diabetes.

The company said that insulin-naive type 2 diabetes patients treated with premixed modern insulin NovoMix 30 (biphasic insulin aspart) experienced a 2.4 percentage point reduction in HbA1c levels.

Furthermore, this improvement was more pronounced in patients who had not received any prior pharmaceutical therapy for their condition, who experienced a reduction of 3.2 percentage points.

In the study, 0.1 per cent of patients reported the adverse event of major hypoglycaemia.

NovoMix 30 is a premixed, dual-acting modern insulin that contains 30 per cent rapid-acting insulin and 70 per cent intermediate acting insulin.

Professor Kawamori of the Juntendo University School of Medicine in Tokyo, said: “[The results] confirm that the vast majority of poorly controlled patients who are new to insulin can rely on a simple twice-daily injection of NovoMix 30 to reduce their HbA1c to acceptable levels.”

He added this reduction in blood glucose levels can subsequently improve patients’ quality of life by a significant degree.

Earlier this month, Novo Nordisk announced the launch of its next-generation pre-filled FlexPen insulin delivery device.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.